fda bans compounded semaglutide and tirzepatide September 2, 2025: U.S. compounding restrictions have stemmed a flood of – Partnership for Safe Medicines New project announcement: HHS‑OIG is

With just four steps from treatment to reimbursement pet parents can better manage both their pets health needs and their own budget

This guide cuts through that with the clinical protocols Beyond Stem Cells actually uses, the math behind the doses, and the safety boundaries that matter

once before breakfast

Arch Biochem Biophys (2025) 768:110366

(T)aking GLP-1RAs may be associated with an increased risk of kidney cancer, highlighting the need for longer-term follow-up to clarify the underlying mechanisms and clinical implications of these findings. GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity, JAMA Oncology Despite the risks being slight, researchers noted that there were more than 137 million individuals currently eligible to take GLP-1 medications in the U.S., and that even modest changes in cancer risk could have substantial public health implications. Ozempic, Mounjaro Gastroparesis Lawsuits Individuals nationwide are pursuing more than 2,400 product liability lawsuits brought throughout the federal court system over the past two years, each indicating that Novo Nordisk and Eli Lilly, the manufacturers of Ozempic and Mounjaro respectively, failed to provide adequate warning that the diabetes and weight loss drugs could cause severe gastrointestinal problems